GlassScriptPhysician profile
Shawn Kade
NPI 1033866371
$2,744.58
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $779 · 2023: $1,917 · 2024: $48.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $618.11 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $379.25 | 2022-2023 | Invega Trinza, Invega Sustenna, Spravato |
| Alkermes, INC. | $309.39 | 2022-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $292.56 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $229.83 | 2022-2023 | Austedo Xr, Austedo, Uzedy |
| Neos Therapeutics, LP | $155.91 | 2022-2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Axsome Therapeutics, INC. | $151.79 | 2022-2023 | Auvelity |
| Indivior INC. | $136.93 | 2022-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $119.49 | 2023 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $97.19 | 2022-2023 | Trintellix |
| Corium, LLC | $86.68 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $73.76 | 2022-2023 | Rexulti, Abilify Maintena |
| Braeburn INC. | $59.98 | 2023 | Brixadi |
| Almatica Pharma LLC | $33.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Kade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.